INTRODUCTION
============

Tuberous sclerosis complex (TSC) is a genetic disorder caused by loss of function of the *TSC1* or *TSC2* genes. Individuals with this disorder have multi-organ hamartomas resulting from increased proliferation and abnormal differentiation. Although not malignant, these tumors can still cause severe clinical manifestations, particularly in the brain, kidney and lungs ([@b5-0060925]). The protein products of the *TSC1* (hamartin) and *TSC2* (tuberin) genes bind to each other and function together to modulate downstream signaling pathways. Rapid advances in our knowledge of TSC were catalyzed by the discovery that hamartin-tuberin normally inhibits the mechanistic target of rapamycin (mTOR; previously known as mammalian target of rapamycin) serine/threonine kinase ([@b44-0060925]). mTOR is found within two functionally and molecularly distinct complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Further intricacies are apparent because loss of *TSC1* or *TSC2* gene function seems to allow broadly dysregulated mTOR activity with constitutively increased mTORC1 activity but also decreased mTORC2 signaling ([@b19-0060925]; [@b21-0060925]; [@b33-0060925]; [@b41-0060925]). Through a very rapid translation of basic science findings, therapies with mTORC1 inhibitors have been developed as effective treatments for some of the clinical manifestations of TSC ([@b6-0060925]; [@b12-0060925]).

It is striking that patients with TSC almost as a rule develop benign tumors instead of malignancies. In contrast, patients with *PTEN* mutations also have constitutive activation of mTORC1 signaling but develop frank malignancies including aggressive gliomas ([@b17-0060925]). Several models have been proposed to account for the relative lack of malignancy, including feedback inhibition of AKT by mTORC1 activation, altered mTORC2 function as well as increased rates of apoptotic cell death in *TSC1-* or *TSC2*-deficient cells. Increased cell death might then balance excessive proliferation and thus prevent the emergence of transformed cells that could ultimately form malignancies. In support of this model, either *TSC1-* or *TSC2*-deficient cells *in vitro* are prone to apoptosis, particularly when under metabolic stress ([@b4-0060925]).

*TP53* (*p53*) is one of the most frequently mutated genes in human cancer ([@b11-0060925]; [@b28-0060925]; [@b47-0060925]). As a tumor suppressor, p53 protein regulates growth arrest and apoptosis ([@b48-0060925]), and has many identified transcriptional targets ([@b40-0060925]; [@b46-0060925]). Approximately 50% of all human cancers have a mutation in p53 that alters its transcriptional activity ([@b7-0060925]) (<http://p53.fr/>). However, many questions remain regarding downstream molecular pathways involved in tumor cell growth. Recent studies have suggested an emerging role for p53 in cellular metabolism ([@b30-0060925]) during stress conditions, including nutrient deprivation and hypoxia. This suggests a functional interaction with the mTOR signaling pathway. In addition, ∼40--90% of human malignancies have increased mTORC1 signaling ([@b36-0060925]). p53 is also known to regulate transcription of the *PTEN* gene, an upstream inhibitor of AKT signaling, as well as *TSC2* (tuberin), an upstream inhibitor of mTORC1 signaling ([@b10-0060925]; [@b43-0060925]). Furthermore, mTORC1 regulates the translation of *p53 in vitro* ([@b26-0060925]). These findings suggest mechanistic links between mTORC1 and p53 that might be important for TSC pathogenesis, and possibly explain the paucity of cancer in patients with TSC.

###### TRANSLATIONAL IMPACT

**Clinical issue**

Tuberous sclerosis complex (TSC) is a genetic disorder caused by loss-of-function mutations of the *TSC1* gene (which encodes hamartin) or the *TSC2* gene (which encodes tuberin). Hamartin and tuberin bind to each other and inhibit the mechanistic target of rapamycin (mTOR) serine/threonine kinase, which is found in two functionally and molecularly distinct complexes (mTORC1 and mTORC2). Loss of *TSC1* or *TSC2* gene function constitutively increases mTORC1 signaling and decreases mTORC2 signaling. Strikingly, individuals with TSC develop multi-organ hamartomas that, with rare exceptions, are non-cancerous, whereas other groups of patients with constitutive activation of mTORC1 signaling develop frank malignancies. A better understanding of this apparent paradox might provide new insights into the genetic mechanisms underlying cancer pathogenesis.

**Results**

Previous work by this group demonstrated that *tsc2* homozygous mutant zebrafish recapitulate several key aspects of TSC, including hamartoma formation in the brain and increased mTORC1 signaling. In this study, the authors generate a zebrafish model of TSC and cancer progression by placing a heterozygous mutation of the *tsc2* gene in a *p53* mutant background. They show that *tsc2* heterozygous mutant zebrafish never develop cancers but that *tsc2;p53* compound mutants develop multi-organ malignancies that are seen earlier and in more tissue types than in zebrafish that are mutant for *p53* alone. Both mTORC1 and mTORC2 signaling are altered in *tsc2;p53* compound mutant zebrafish compared with *p53* mutant zebrafish. Moreover, there is increased angiogenesis in tumors from *tsc2;p53* compound mutants than in tumors from *p53* mutant zebrafish. Notably, treatment of *tsc2;p53* compound mutants with rapamycin, an mTORC1 inhibitor, decreases tumor size and the caliber of tumor-associated blood vessels.

**Implications and future directions**

These findings suggest that the lack of progression to cancer in patients with TSC might be mediated by p53-dependent senescence and that additional genetic changes such as the loss of *TP53* are likely to be required for progression to malignancy. They provide new insights into the interactions between tuberin-mTORC1 signaling and p53 during tumorigenesis and suggest that, in patients without TSC, heterozygous *TSC1* or *TSC2* mutations in tumors that already carry *TP53* mutations might lead to the development of more severe forms of cancer. Finally, these findings suggest that inhibition of mTORC1 signaling might be a viable therapeutic option for p53-deficient tumors in patients without TCS as well as in patients with TCS.

Zebrafish have emerged as a powerful model for the study of genetic diseases as well as cancer ([@b8-0060925]; [@b14-0060925]; [@b37-0060925]). This is due to ease of genetic manipulation in zebrafish, the aneuploid nature of cancers arising in zebrafish, and the capacity of these animals for high-throughput genetic and pharmacologic screens ([@b50-0060925]; [@b51-0060925]). We previously showed that *tsc2* homozygous mutant (*tsc2^vu242/vu242^*) zebrafish recapitulate several key aspects of TSC, including control of cell size, hamartoma formation in the brain and increased mTORC1 signaling ([@b23-0060925]). *p53* mutant zebrafish models showed a conserved role for p53 in tumorigenesis ([@b2-0060925]; [@b39-0060925]), with the *p53^zdf1^* allele being functionally similar to DNA-binding domain mutations identified in cancers from many patients.

To define interactions of the p53 and mTOR signaling pathways, we first examined mTORC1 signaling in tumors arising from *p53^zdf1/zdf1^* homozygous mutant zebrafish and found that it was increased compared with that found in normal tissues from wild-type fish. We then explored a potential role for mTORC1 signaling in *p53*-mutation-mediated tumor formation by investigating whether further increases of mTORC1 activity enhance tumorigenesis. We used *tsc2^vu242/+^;p53^zdf1/zdf1^* compound mutant (*tsc2;p53* compound mutant) zebrafish for this purpose. These zebrafish had altered mTORC1 and mTORC2 signaling and enhanced rates of tumorigenesis compared with that seen with *p53* mutations alone. We found increased expression of Hif1-α, Hif2-α and Vegf-c that was associated with prominent angiogenesis in tumors from *tsc2;p53* compound mutant compared with *p53* mutant zebrafish. Transient administration of rapamycin, a potent mTORC1 inhibitor, rapidly diminished the tumor-associated blood vessels. These results provide the first *in vivo* evidence of a crucial role of p53 to prevent the formation of malignancies in TSC.

RESULTS
=======

Activation of mTORC1 signaling in *p53* mutant tumors
-----------------------------------------------------

To examine the contribution of mTOR activity in tumors arising from *p53* mutant zebrafish, we measured mTORC1 signaling activity in abdominal tumors spontaneously arising from homozygous *p53* mutant zebrafish ([Fig. 1A](#f1-0060925){ref-type="fig"}). Histological analyses of these *p53* mutant abdominal tumors revealed spindle-like cells reminiscent of malignant sarcomas. These cells were highly invasive, destroying skeletal muscle fibers ([Fig. 1B](#f1-0060925){ref-type="fig"}; [Fig. 2A](#f2-0060925){ref-type="fig"}). Similar pathological features were previously described in this zebrafish model ([@b2-0060925]). Using immunofluorescence, we next determined expression of phosphorylated ribosomal protein S6 (phospho-S6) and phosphorylated eukaryotic initiation factor 4E-binding protein 1 (phospho-4E-BP1), well established downstream effectors of the mTOR kinase within mTORC1 ([@b18-0060925]). These abdominal tumors had high expression of both phospho-S6 and phospho-4E-BP1 ([Fig. 1C,D](#f1-0060925){ref-type="fig"}; [supplementary material Fig. S1, upper panel](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.011494/-/DC1)) in a subset of tumor cells. Immunoblot analyses also revealed a moderate increase of mTORC1 signaling in normal appearing eyes from *p53^zdf1/zdf1^* zebrafish compared with wild-type control eyes (data not shown). These results suggest that mTORC1 activation in *p53* mutant tissues might facilitate tumor formation and/or growth.

![**mTORC1 signaling in malignant abdominal tumors in *p53^zdf1/zdf1^* zebrafish.** (A) 1-year-old *p53^zdf1/zdf1^* mutant fish with prominent abdominal tumor. (B) Hematoxylin and eosin (H&E) staining of a section from an abdominal tumor showing whorls of spindle-shaped cells consistent with an invasive sarcoma. (C,D) Increased expression of mTORC1 downstream effectors phospho-S6 (C) and phospho-4EBP1 (D) in abdominal tumors from *p53^zdf1/zdf1^* zebrafish. For C and D, red fluorescence is immunosignal and blue is DAPI nuclear stain. M, muscle; T, tumor. Scale bars: 100 μm. Similar findings were seen in abdominal tumors from 10/10 *p53^zdf1/zdf1^* zebrafish.](DMM011494F1){#f1-0060925}

![**Increased mTORC1 signaling, enhanced tumorigenesis and altered tumor spectrum from the addition of a *tsc2* heterozygous allele to a *p53^zdf1/zdf1^* background.** (A) H&E, phospho-S6 and DAPI (nuclei) staining of abdominal tumors from *p53^zdf1/zdf1^* and *tsc2;p53* compound mutant zebrafish. Left panels: invasive region of a *p53^zdf1/zdf1^* tumor; right panels: *tsc2;p53* compound mutant tumor. Circular structures are skeletal muscle bundles encircled by invasive tumor cells (pink in the H&E staining, but dark areas in the immunofluorescence images). Phospho-S6 signal is red and DAPI is white. M, muscle; T, tumor. Scale bar: 100 μm. (B) Kaplan-Meier tumor-free survival. Blue line is *p53^zdf1/zdf1^* zebrafish, red line is *tsc2;p53* compound mutant zebrafish. 50% of *p53^zdf1/zdf1^* zebrafish had tumors at ∼550 days of life compared with 450 days for *tsc2;p53* compound mutant zebrafish. *n*=115 and 130, respectively. This reduction in latency to tumor detection was statistically significant using the Log-rank test (*P*\<0.0001). (C) Spectrum of tumor types from *p53^zdf1/zdf1^* and *tsc2;p53* compound mutant zebrafish. Tumor types were broadly similar with the exception of melanoma-like tumors, which were seen only in *tsc2;p53* compound mutant zebrafish. (D) Normal zebrafish head and dorsal fin in the top panels and melanoma-like tumors on the head and dorsal fin in the bottom panels. Dorsal fins were sectioned at the region marked '1' (normal) and '2' (tumor) and stained with DAPI in D′ and D″, respectively. Scale bars: 5 mm (D); 100 μm (D″).](DMM011494F2){#f2-0060925}

Heterozygous *tsc2^vu242^* mutation enhanced mTORC1 signaling activity and tumor incidence in *p53^zdf1/zdf1^* zebrafish
------------------------------------------------------------------------------------------------------------------------

Given the increased mTORC1 signaling in *p53* mutant zebrafish tumors, we hypothesized that further augmentation of mTORC1 signaling might enhance tumor formation, cell growth or tumor severity. To test this hypothesis, we introduced a heterozygous *tsc2^vu242^* mutation into *p53^zdf1/zdf1^* mutant zebrafish. We previously reported that heterozygous *tsc2^vu242^* mutant zebrafish are viable and have moderately elevated mTORC1 signaling activity ([@b23-0060925]). Of note, tumors were never seen in heterozygous *tsc2^vu242/+^* zebrafish, including in zebrafish of 2 years of age or older (*n*\>200). In contrast, adult *tsc2;p53* compound mutant zebrafish developed large sarcomatous tumors in the abdomen ([Fig. 2A](#f2-0060925){ref-type="fig"}) as well as in other regions ([Fig. 2C](#f2-0060925){ref-type="fig"}). Immunostaining for phospho-S6 levels confirmed prominent mTORC1 activation within tumors from compound mutant zebrafish, and these levels were further augmented when compared with tumors from *p53^zdf1/zdf1^* zebrafish ([Fig. 2A](#f2-0060925){ref-type="fig"}; [supplementary material Fig. S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.011494/-/DC1)). As previously reported, these malignancies have a long latency, with 50% of *p53^zdf1/zdf1^* zebrafish exhibiting tumors by 550 days of life (*n*=115 total *p53^zdf1/zdf1^* zebrafish, [Fig. 2B](#f2-0060925){ref-type="fig"}). In contrast, 50% of *tsc2;p53* compound mutant zebrafish had tumors by 450 days of life (*n*=130 total *tsc2;p53* compound mutant zebrafish, [Fig. 2B](#f2-0060925){ref-type="fig"}, compared with *p53^zdf1/zdf1^* zebrafish, Log-rank test, *P*\<0.0001). Types of tumors were broadly similar in *p53^zdf1/zdf1^* and *tsc2;p53* compound mutant zebrafish, with the exception of melanoma-like tumors. These were seen in ∼7% of *tsc2;p53* compound mutant zebrafish ([Fig. 2C](#f2-0060925){ref-type="fig"}), but never seen in *p53^zdf1/zdf1^* homozygous mutant zebrafish. Melanoma-like tumors were not reported in the original report of the *p53^zdf1/zdf1^* phenotype ([@b2-0060925]). However, melanoma-like skin tumors were frequently observed in a different zebrafish model featuring a more deleterious *p53* mutation ([@b39-0060925]).

mTORC1 and mTORC2 signaling in tumors from *p^53zdf1/zdf1^* and *tsc2;p53* compound mutant zebrafish
----------------------------------------------------------------------------------------------------

We next quantitated mTOR signaling levels using protein extracts from a consecutive series of abdominal tumors arising in *p53^zdf1/zdf1^* and *tsc2;p53* compound mutant zebrafish. In support of our immunostaining data presented in [Figs 1](#f1-0060925){ref-type="fig"} and [2](#f2-0060925){ref-type="fig"}, we again found increased phospho-S6 levels in a series of tumors arising from *tsc2;p53* compound mutant zebrafish compared with those from *p53^zdf1/zdf1^* zebrafish ([Fig. 3A,B](#f3-0060925){ref-type="fig"}). When normalized for total S6, the ratio of phospho-S6 to total S6 was significantly higher in abdominal tumors arising from *tsc2;p53* compound mutant zebrafish compared with *p53^zdf1/zdf1^* zebrafish ([Fig. 3D](#f3-0060925){ref-type="fig"}). We also looked at other tumor types and again found increased mTORC1 signaling in *tsc2;p53* compound mutant zebrafish compared with tumors from *p53^zdf1/zdf1^* zebrafish (data not shown). Finally, we quantified mTORC2 signaling in abdominal tumor extracts by immunoblotting for Akt (Ser473) levels and found no significant differences between *tsc2;p53* compound mutant and *p53^zdf1/zdf1^* zebrafish ([supplementary material Fig. S2](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.011494/-/DC1)).

![**Increased mTORC1 signaling in tumors arising from *tsc2;p53* compound mutant zebrafish compared with *p53^zdf1/zdf1^* zebrafish.** (A) Immunoblotting of a series of abdominal tumors comparing *p53^zdf1/zdf1^* mutant zebrafish (lanes marked Tsc2^+/+^) and *tsc2;p53* compound mutants (lanes marked Tsc2^+/−^). (B) Quantification of phospho-S6 levels were normalized to actin expression (*P*=0.25). (C) Quantification of total S6 levels were normalized to actin expression (*P*=0.06). (D) Increased ratio of normalized phospho-S6 to total S6 levels in *tsc2;p53* compound mutant compared with *p53^zdf1/zdf1^* zebrafish; asterisk denotes significance by two-tailed Student's *t*-test, *P*=0.03. *n*=5 for *p53* mutant and *n*=7 for compound mutant zebrafish, although two tumor samples from *tsc2;p53* compound mutant zebrafish (lanes 4,5 and 11,12) were divided in half and processed independently for immunoblotting.](DMM011494F3){#f3-0060925}

Elevated Akt kinase activity in tumors from *p^53zdf1/zdf1^* and *tsc2;p53* compound mutant zebrafish
-----------------------------------------------------------------------------------------------------

p53 activates transcription of the *PTEN* gene and increased levels of PTEN protein *in vitro* can suppress AKT activation. This can relieve the inhibitory phosphorylation of tuberin at Ser939 and Thr1462 by AKT kinases ([@b32-0060925]; [@b10-0060925]). Although these signaling cascades have been described, genetic interactions of AKT and mTOR signaling have not been well characterized *in vivo*. To further address Akt activity in tumors from *p53^zdf1/zdf1^* and *tsc2;p53* compound mutant zebrafish, we examined phospho-tuberin (Ser939) using immunofluorescence. We found strongly positive cells within both tumor types, although there was a clear elevation in abdominal tumors from *tsc2;p53* compound mutant zebrafish ([Fig. 4A--F](#f4-0060925){ref-type="fig"}; [supplementary material Fig. S3](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.011494/-/DC1)). We attempted to use this phospho-antibody for immunoblotting but did not obtain interpretable results. To further address Akt activity in these tumors, we also performed immunofluorescence using antibodies against total Akt, phospho-Akt (Thr308) and phospho-Akt (Ser473) ([Fig. 4G--L](#f4-0060925){ref-type="fig"}; [supplementary material Figs S4](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.011494/-/DC1), [S5](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.011494/-/DC1)). Interestingly, we found that the total Akt level was diffusely increased in tumor cells compared with adjacent muscle tissues from both *p53^zdf1/zdf1^* and *tsc2;p53* compound mutant zebrafish ([Fig. 4G,J](#f4-0060925){ref-type="fig"}, *n*=8/8; [supplementary material Fig. S4](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.011494/-/DC1)). Phospho-Akt (Thr308) levels were comparable, although the signal from *tsc2;p53* compound mutant tumors were increased compared with *p53^zdf1/zdf1^* tumors ([Fig. 4H,K](#f4-0060925){ref-type="fig"}; [supplementary material Fig. S5](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.011494/-/DC1)). In contrast, phospho-Akt (Ser473) levels were somewhat decreased in tumor cells ([Fig. 4I,L](#f4-0060925){ref-type="fig"}) compared with adjacent muscle. Because Ser473 of Akt is phosphorylated by mTORC2, this reduction might be due to negative feedback by activated mTORC1 ([@b16-0060925]; [@b42-0060925]).

![**AKT activity in *p53^zdf1/zdf1^* and *tsc2;p53* compound mutant tumors.** (A--F) Phospho-tuberin (p-Tsc2) staining in *p53^zdf1/zdf1^* and *tsc2;p53* compound mutant zebrafish. (B,C and E,F) Higher magnification of A and D, respectively. (C,F) Phospho-tuberin (Ser939, red); (B,E) phospho-tuberin (red) merged with DAPI (blue). (G,J) Total Akt immunofluorescence, (H,K) phospho-Akt (Thr308) immunofluorescence and (I,L) phospho-Akt (Ser473) immunofluorescence in *p53^zdf1/zdf1^* (G--I) and *tsc2;p53* compound mutant (J--L) zebrafish. M, muscle; T, tumor. Scale bars: 100 μm.](DMM011494F4){#f4-0060925}

Vegf upregulation in tumors from *p^53zdf1/zdf1^* and *tsc2;p53* compound mutant zebrafish
------------------------------------------------------------------------------------------

As we assessed tumors arising in *p53^zdf1/zdf1^* and *tsc2;p53* compound mutant zebrafish, we frequently noted prominent and abnormal appearing blood vessels in the abdomen and eyes from both mutant genotypes (*n*=25/41 with tumors, [Fig. 5A--D](#f5-0060925){ref-type="fig"}). This was consistently enhanced in tumors from *tsc2;p53* compound mutant as compared with *p53^zdf1/zdf1^* zebrafish. Approximately 68% of *tsc2;p53* compound mutant zebrafish with abdomen and eye tumors developed thin blood vessels (*n*=10/25) but some abnormal vessels were also massively dilated (*n*=7/25, [Fig. 5C,D](#f5-0060925){ref-type="fig"}). By comparison, about 50% of *p53^zdf1/zdf1^* mutants with abdomen and eye tumors exhibited thin (*n*=5/16, [Fig. 5A,B](#f5-0060925){ref-type="fig"}) or dilated blood vessels (*n*=3/16), but the degree of dilation was not as marked when compared with abnormal dilated blood vessels in *tsc2;p53* mutants (comparison to *tsc2;p53* mutants not statistically significant with *P*=0.33 by two-tailed Fisher's exact test). These findings suggest that angiogenesis is enhanced in tumors arising from *tsc2;p53* compound mutant zebrafish as compared with those arising in *p53^zdf1/zdf1^* zebrafish. To see whether there was altered expression of angiogenic factors, we performed immunostaining for Hif1-α, Hif2-α and Vegf-c. All of these angiogenic factors were expressed in *p53^zdf1/zdf1^* tumors with more intensive staining again seen in *tsc2;p53* compound mutant zebrafish ([Fig. 5E--K](#f5-0060925){ref-type="fig"}; [supplementary material Figs S6](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.011494/-/DC1), [S7](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.011494/-/DC1)). These results suggest that further increases in mTORC1 signaling from *tsc2* heterozygote zebrafish in a *p53* mutant background possibly increases angiogenesis and vasodilation via upregulation of Hif1-α, Hif2-α and Vegf-c expression.

![**Angiogenesis and increased expression of angiogenic factors in tumors from *tsc2;p53* compound mutant zebrafish.** (A,B) Arrowheads indicate visible blood vessels on tumors from abdomen (A) and eye (B) from *p53^zdf1/zdf1^* zebrafish (*n*=8/16). (C,D) Arrowheads indicate large and tortuous blood vessels observed in abdomen (C) and eye (D) tumors from *tsc2;p53* compound mutant (*n*=17/25) zebrafish. Scale bars: 1 mm. (E,H) Hif1-α staining, (F,J) Hif2-α staining and (G,K) Vegf-c staining in *p53^zdf1/zdf1^* (E--G) and *tsc2;p53* compound mutant (H--K) zebrafish. Scale bar: 100 μm.](DMM011494F5){#f5-0060925}

Rapamycin treatment suppresses Vegf expression in tumors from *p^53zdf1/zdf1^* and *tsc2;p53* compound mutant zebrafish
-----------------------------------------------------------------------------------------------------------------------

Given the increased expression of angiogenesis factors in these tumors, we next determined whether inhibition of mTORC1 signaling could suppress blood vessel formation and tumor size. Application of rapamycin daily seemed to shrink the caliber of existing blood vessels (example of an eye tumor in [Fig. 6A,B](#f6-0060925){ref-type="fig"}). A representative vessel ([Fig. 6B, black arrowheads](#f6-0060925){ref-type="fig"}) seemed to completely disappear at the end of both rapamycin treatment cycles (day 3 and day 14) but became visible again during the rapamycin 'off period' (day 6 and day 9) in the same location. This result supports a vasoconstrictive effect of rapamycin, probably through inhibition of Vegf-induced vasodilation ([@b22-0060925]). During a rapamycin 6-day 'off period' in *tsc2;p53* compound mutant zebrafish, re-dilated vessels appeared ([Fig. 6B, black arrowhead](#f6-0060925){ref-type="fig"}) as well as possible neoangiogenesis where vessels were not previously seen (example shown in [Fig. 6B, blue arrowhead at day 6](#f6-0060925){ref-type="fig"}). These results suggest that activation of mTORC1 signaling is essential for neoangiogenesis and dilation of blood vessels in tumors arising in a *p53^zdf1/zdf1^* background. To verify the effect of rapamycin treatment, we performed immunostaining with antibodies against phospho-S6, phospho-4EBP1, Akt and Vegf-c in abdominal tumors treated with vehicle (DMSO) or rapamycin daily for 2 days ([Fig. 6C](#f6-0060925){ref-type="fig"}). Rapamycin treatment decreased mTORC1 signaling as evidenced by lower levels of phospho-S6 and phospho-4E-BP1 in rapamycin-treated tumors ([Fig. 6C](#f6-0060925){ref-type="fig"}). Furthermore, we found that total Akt expression levels were also downregulated by rapamycin, although this suppression was mainly observed in the inner region of tumors.

![**Rapamycin treatment reduced blood vessel caliber in tumors from *p53^zdf1/zdf1^* and *tsc2;p53* compound mutant zebrafish.** (A,B) Representative tumors from rapamycin-treated fish. (A) Rapamycin treatment of *p53^zdf1/zdf1^* zebrafish harboring a tumor in its trunk. Arrowheads indicate visible vascular structure on the tumor surface. (B) Rapamycin treatment cycle (on day 0 to 3, 9 to 14, off day 4 to 8) lasting 2 weeks in a compound mutant zebrafish with an expending eye tumor. Pictures were taken at indicated days. Black arrowheads indicate vascular structures that disappeared during rapamycin treatment. Blue arrowhead indicates apparent new vessels formed during the rapamycin-off period. (C) H&E staining, and phospho-S6, phospho-4EBP1, Akt and Vegf-c expression (antibody signal shown as white) in *p53^zdf1/zdf1^* and *tsc2;p53* compound mutant abdomen tumors treated with DMSO or rapamycin for 2 days (*n*=3). Scale bar: 100 μm. (D) Rapamycin shrinks tumors in *p53^zdf1/zdf1^* zebrafish. A representative angioma-like tumor was seen near the pectoral fin and treated daily with rapamycin. After 3 days of treatment, a clear decrease in size was noted. The tumor continued to shrink over the 1 week total period of rapamycin treatment. Scale bar: 1 mm.](DMM011494F6){#f6-0060925}

mTORC1 inhibitors decrease tumor size
-------------------------------------

Given the rapid effect of rapamycin on blood vessel caliber and regression, we investigated whether continued treatment could reduce the size of tumors. We treated several types of rapidly growing tumors and found either stabilization of tumor size or a reduction in size during daily rapamycin treatments ([Fig. 6](#f6-0060925){ref-type="fig"}; [supplementary material Fig. S7](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.011494/-/DC1)). This effect was seen in tumors from *p53^zdf1/zdf1^* zebrafish as well as those from *tsc2;p53* compound mutants. In all cases, there was rapid resumption of tumor growth after rapamycin was stopped.

DISCUSSION
==========

This study was designed to investigate why patients with TSC almost never develop cancer despite high levels of mTORC1 signaling in multiple organs. This is in contrast to the malignancies typically seen in patients with increased mTORC1 signaling due to *PTEN* mutations ([@b17-0060925]; [@b20-0060925]). Various models have been proposed to explain this striking discrepancy, including feedback inhibition of AKT through mTORC1 and direct or indirect reductions of mTORC2 activity ([@b33-0060925]). Alternatively, decreased cell proliferation and enhanced cell death in *TSC1-* or *TSC2*-deficient cells might compensate for any excessive proliferation induced by increased mTORC1 activity. This model is also supported by complications reported during the generation of mouse embryonic fibroblasts (MEFs) from *Tsc2* knockout mice ([@b49-0060925]). Although derived *Tsc2* mutant MEFs initially grew as expected, they rapidly underwent senescence and died. However, the authors circumvented this problem by crossing the *Tsc2* knockout allele into *p53*-deficient mice. The resulting *Tsc2/p53* mutant embryos were then used to generate MEFs that were capable of continuous growth. Our *in vivo* results using a zebrafish animal model of TSC further support that senescence in *Tsc2* mutant cells might be mediated by p53. The loss of both *tsc2* and *p53* gene function might then permit uncontrolled proliferation leading to malignancies.

There are multiple types of benign tumors in TSC, including brain subependymal giant cell astrocytomas (SEGAs), angiomyolipomas in the kidney and rhabdomyomas in the heart. One notable exception is renal cell carcinoma (RCC). Although RCC is rarely seen in patients with TSC, it has been reported in relatively young patients ([@b27-0060925]). This is potentially quite relevant to our results because RCCs usually harbor *p53* mutations ([@b13-0060925]; [@b15-0060925]; [@b38-0060925]). This further suggests that, in TSC, an additional mutation of *p53* might allow progression to malignancy. Direct support for this model will require analyses of *p53* status in RCC obtained from patients with TSC. Additional deep sequencing of TSC-associated hamartomas for any *p53* mutations would also support or refute this model.

Our finding of enhanced tumor formation in *tsc2;p53* compound mutant zebrafish is supported by previous reports of substantial crosstalk between p53, AKT and mTOR signaling during tumorigenesis. For example, p53 activates transcription of *PTEN*, a phosphoinositide phosphatase that normally inhibits AKT signaling ([@b10-0060925]). In addition, AKT and mTORC1 signaling is frequently activated in ovarian ([@b1-0060925]) and lung ([@b35-0060925]) cancers, which usually have *p53* mutations. Furthermore, p53 *in vitro* can inhibit mTOR signaling via the hamartin-tuberin complex ([@b9-0060925]). A recent study also indicated that signaling components downstream of mTOR can modulate p53 through the signaling of ribosomal S6 kinase to MDM2, a ubiquitin ligase that controls p53 stability ([@b24-0060925]). Thus, the p53 signaling pathway incorporates AKT and mTORC1 ([@b29-0060925]). However, interactions between p53 and mTOR pathway components during tumor formation have not been previously well studied *in vivo*.

Differential activation of Hif1-α and Hif2-α by mTORC1 and mTORC2 has been reported using *in vitro* assays ([@b45-0060925]). The expression of Hif1-α and Hif2-α was dependent on Akt3 and Akt2, respectively. The effect of rapamycin treatment to blood vessel maintenance is also indicative of an mTORC1-dependent regulation of proangiogenic factors. However, the rapid return of blood vessels when rapamycin treatment was stopped supports a vasoconstrictive mechanism that has been previously suggested ([@b22-0060925]). Vegf-c expression, one of the central regulators of blood vessel formation, was also suppressed by rapamycin treatment, this affect was also most apparent in the inner part of the tumor ([Fig. 6C](#f6-0060925){ref-type="fig"}). Altogether, these results suggest that mTORC1 activation plays an important role in tumor angiogenesis in *p53* mutant tissues. In support of this model, we also found increased blood vessel size in the livers of *tsc2* homozygous mutants compared with control Tg(*Fli1*:EGFP) zebrafish larvae ([supplementary material Fig. S8](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.011494/-/DC1)). An additional feedback pathway that results from tuberin deficiency is increased PTEN activity via a rapamycin-dependent mechanism ([@b3-0060925]; [@b31-0060925]; [@b34-0060925]). We are currently testing this potential mechanism by placing a *tsc2* heterozygous allele in a *pten* mutant background and again analyzing resultant zebrafish for the development of malignant tumors. AMPK might also be involved as this kinase normally interacts with p53 and tuberin to modulate cell proliferation. We found that activated phospho-AMPK (Thr172) was increased in tumor cells from both *p53^zdf1/zdf1^* and *tsc2;p53* compound mutant zebrafish ([supplementary material Fig. S9](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.011494/-/DC1)). This might be due to a feedback loop uncovered in mutant zebrafish, because activated AMPK normally phosphorylates tuberin to activate it and inhibit mTORC1 signaling.

Of note, we have never seen sarcomas arising in *tsc2* heterozygous zebrafish. This is broadly consistent to what is observed in human patients with TSC as well as rodent models of this disorder. *tsc2;p53* compound mutant zebrafish have an significantly decreased time to tumor detection compared with *p53^zdf1/zdf1^* zebrafish. However, it is possible that tumors arising in *tsc2;p53* compound mutant zebrafish are simply faster growing, leading to their earlier detection. This is possible, although even within the oldest groups of zebrafish (\>2 years old), *tsc2;p53* compound mutant zebrafish always exhibited more tumors than *p53^zdf1/zdf1^* zebrafish.

We conclude that additional genetic changes such as loss of *TP53* are probably required for the progression to malignancy in TSC. Our results might also have implications for non-TSC patients if additional tumor-specific heterozygous *TSC1* or *TSC2* mutations in the setting of existing or subsequent *TP53* mutations can potentially lead to more severe forms of cancer. The expected increased mTORC1 signaling in this scenario suggests that mTORC1 inhibitors could be effective therapies for such cancers. Further application of full exome and genome sequencing will likely uncover additional evidence of genetic interactions between *TP53* and both *TSC1* and *TSC2* in a variety of human cancers.

MATERIALS AND METHODS
=====================

Zebrafish strains
-----------------

Zebrafish strains used in this study included *tsc2^vu242^*^/+^ ([@b23-0060925]) and *p53^zdf1/zdf1^* ([@b2-0060925]). Five pairs of *tsc2;p53* compound mutant zebrafish (*tsc2^vu242/+^;p53^zdf1/zdf1^*) and *p53^zdf1/zdf1^* adult fish were mated and embryos raised at 28.5°C. 5-month-old zebrafish siblings were genotyped and *p53^zdf1/zdf1^* and *tsc2;p53* compound mutant zebrafish identified and raised for up to 20 months in separate tanks. For genotyping of *tsc2^vu242/+^*, we amplified a 151 bp fragment by PCR using forward primer 5′-CCAGCACCACCTGCAGTCTGG-3′ and reverse primer 5′-CTCTTGGGCAGAGCAGAGAAGTTGG-3′ flanking the mutation site. The point mutation was confirmed by absence of a HpyCh4IV restriction site. Tg(*Fli1:*EGFP) zebrafish ([@b25-0060925]) were obtained from the Zebrafish International Resource Center (ZIRC). All experiments were approved by the Vanderbilt Institutional Animal Care and Use Committee (IACUC).

Tumor analyses
--------------

For 550 days, adult fish (total of 110 *p53^zdf1/zdf1^* and 130 *tsc2;p53* compound mutant zebrafish) were monitored twice per week for tumor development or death. Fish noted to have a prominent tumor were euthanized in 20% MESAB and dissected into four pieces (head, anterior abdomen, posterior abdomen and tail). Pieces containing tumor were fixed in 4% paraformaldehyde for 2 days at 4°C. Fixed bodies were embedded in 1.2% agarose/5% sucrose and saturated in 30% sucrose. Tissue blocks were frozen in 2-methyl butane. 10-μm sections were collected on microscope slides using a Leica cryostat. Sections were then kept at −80°C prior to use.

Immunofluorescence
------------------

To minimize staining variation, ten tumor sections of each *p53^zdf1/zdf1^* and *tsc2;p53* compound mutant zebrafish were concurrently processed in a Sequenza™ Slide Rack (Thermo Scientific) (results are shown in [supplementary material Figs S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.011494/-/DC1)--[S3](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.011494/-/DC1)). Sections were rehydrated in 1× PBS for 20 minutes at room temperature and blocked in 5% sheep serum/1× PBS for 2 hours. Antibodies used were against: phospho-S6 ribosomal protein (Ser235/236) (Cell Signaling \#2215), phospho-4E-BP1 (Thr37/46) (Cell Signaling \#2855), phospho-tuberin (Ser939) (Cell Signaling \#3615), Akt (Cell Signaling \#9272), phospho-Akt (Thr308) (Cell Signaling \#2965), phospho-Akt (Ser473) (Cell Signaling \#9271), phospho-AMPK (Thr172) (Cell Signaling \#2535), Hif1-α (Abcam ab8366), Hif2-α (Thermo Scientific FA1-16510) and Vegf-c (Ana Spec 55877). Antibodies were diluted 1:300 and added to sections overnight at 4°C. Cy3-labeled goat anti-rabbit secondary antibody (Jackson ImmunoResearch) was incubated overnight at 4°C. Sections were then washed with 1× PBS for 1 hour and mounted in VECTASHIELD with DAPI (Vector Laboratories). Images were acquired using a Zeiss Axio Imager Z1 and Zeiss AxioCam MRm digital camera. Digital images were then processed using Adobe Photoshop CS5. Images received only minor modifications of contrast with both control and mutant sections always processed in parallel.

Rapamycin treatment
-------------------

After anesthesia of zebrafish with MESAB, 10 μl of rapamycin in DMSO (10 mg/ml, LC Laboratories) was added to a gill for 10 seconds. Fish were then placed back in water where they rapidly recovered. To monitor angiogenesis in zebrafish with tumors, we treated once a day for 1--2 weeks. For zebrafish with abdominal tumors ([Fig. 6](#f6-0060925){ref-type="fig"}), rapamycin treatment was performed for 2 days total.

Immunoblots
-----------

Tumors and control tissues (mixture of organs derived from brain, kidney, intestine and liver of wild-type zebrafish) were lysed in RIPA cell lysis buffer (10 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate with protease and phosphatase inhibitors added), using a motorized pestle grinder to aid in cell disruption. Protein concentrations were determined using a BCA protein assay, loading buffer was added to each sample and heated at 80°C for 10 minutes prior to loading on a gel and electrophoresed using the Invitrogen X-Cell II™ system. Gels were transferred to PVDF membranes, blocked in Odyssey buffer (Li-COR \#927-40000) for 1 hour and incubated with primary antibodies overnight. Primary antibodies were against: phospho-S6 ribosomal protein (Ser240/244; Cell Signaling \#2215; 1:1000), S6 ribosomal protein (Cell Signaling \#2217; 1:1000), phospho-GSK-3α/β (Ser21/9; Cell Signaling \#9331; 1:1000) and β-actin as a loading control (Sigma-Aldrich \#A5441; 1:2000). Secondary antibodies include IRDye^®^ 800CW goat anti-mouse IgG (Li-COR \#926-32210; 1:10,000) and IRDye^®^ 680RD goat anti-rabbit IgG (Li-COR \#926-68071; 1:10,000). Fluorescent-tagged secondary antibodies were visualized with an Odyssey fluorescence scanner and digitized band densities quantitated using ImageJ (version 1.46).
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